Alder BioPharmaceuticals Inc.

A leading biopharmaceutical company, Alder BioPharmaceuticals Inc. was founded in 2002 to revolutionise treatment for migraines. Alder discovers and develops therapeutic antibodies that provide quality relief for migraine patients in places such as Australia, Ireland and the United States. One such method currently in development by the company is an antibody called eptinezumab. Alder has also developed ALD1910 and Clazakizumab. Alder went public on the Nasdaq exchange in 2014. The IPO was projected to raise approximately $100 million for the company, giving it a market capitalisation of $407 million and a value per share of $14. The Alder stock symbol is ALDR. Major interest in the IPO came from Bristol-Myers Squibb. The pharmaceutical giant, valued at over $80 billion at the time, was considering a total stock purchase that would equal 20% of the IPO. The Washington State-based Alder has collaborated with a company called CSL Limited in the development of therapeutic treatment for organ transplant rejection. Such collaborations are quite common in the healthcare industry, where research and development costs can be fairly taxing. CSL is a biotechnology company located in Australia. Never trade without information. Add ALDR stock to your eToro watchlist.